Both in Biotechnology
Lineage Cell Therapeutics vs SAB Biotherapeutics
Over the past year LCTX returned −42.8% and SABS returned −2.2%; their daily moves had a correlation of 0.19.
LCTX −42.8% SABS −2.2%Growth of $1, one year, split-adjusted
| Metric | LCTX | SABS |
|---|---|---|
| Price | $1.03 | $3.18 |
| Market cap | $260.5M | $289.3M |
| Today | +1.98% | +1.92% |
| 1 month | +9.8% | +8.5% |
| 6 months | −28.0% | −16.3% |
| Year to date | −38.3% | −15.0% |
| 1 year | −47.4% | −2.2% |
| Revenue growth (YoY) | −61.3% | — |
| Gross margin | 100.0% | — |
| Net margin | 138.6% | — |
| P/E (TTM) | — | — |
| Price / sales | 19.9× | — |
| Net cash | $50.8M | $99.4M |
| Dividend yield | — | — |
| Volatility (60d) | 52.5% | 56.6% |
| Short % of float | 12.9% | 6.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).